Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.
about
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the futureAllergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific ImmunotherapySafety of engineered allergen-specific immunotherapy vaccinesVaccines for allergyFood allergies: the basicsA nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.The glycosylation pattern of common allergens: the recognition and uptake of Der p 1 by epithelial and dendritic cells is carbohydrate dependent.Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.Immunization with Hypoallergens of shrimp allergen tropomyosin inhibits shrimp tropomyosin specific IgE reactivityMold allergens in respiratory allergy: from structure to therapy.Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.A folded and immunogenic IgE-hyporeactive variant of the major allergen Phl p 1 produced in Escherichia coliTreatment with 8-OH-modified adenine (TLR7 ligand)-allergen conjugates decreases T helper type 2-oriented murine airway inflammation.Potential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform.Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.Recombinant allergen-based provocation testing.Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.Current developments for improving efficacy of allergy vaccines.Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.Molecular chimerism in IgE-mediated allergy: B-and T-cell tolerance toward highly immunogenic exogenous antigens.Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.Dimerisation increases the immunogenicity of recombinant Parj1/Parj2 allergens.Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.Conformational IgE Epitope Mapping of Der p 2 and the Evaluations of Two Candidate Hypoallergens for Immunotherapy.Mapping of the immunodominant regions of shrimp tropomyosin Pan b 1 by human IgE-binding and IgE receptor crosslinking studies.Efficacy of a therapeutic treatment using gas-filled microbubble-associated phospholipase A2 in a mouse model of honeybee venom allergy.A modified, hypoallergenic variant of the Ricinus communis Ric c1 protein retains biological activity.Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.
P2860
Q26768511-D3060BC9-F251-4A2A-9E58-15A8EC62FBA1Q26852113-23F15D48-99D5-4294-88B2-E0655083D618Q26860962-F02B4C8F-8DEC-4FBF-A9C5-FF65CE887ADFQ27006550-FED31E1F-612D-4B32-98EB-1725177668D8Q27011839-9364CC8D-3C1F-48BC-86E9-1F82A5EF603DQ34106036-61B5E575-357B-47A2-B44E-6BEAE0070CD9Q34221783-B72D5BE0-581E-4BBE-9DF6-FC7E5178664FQ34430399-63BCA32A-53B4-4977-A77A-C56E0364A701Q34445626-E4D16392-5B6F-4F63-884F-07431FE40AA2Q35420488-01281E70-6762-4361-AF7D-ACF60560DB08Q35558343-1CED8D7F-7ED1-43A3-889E-DFD3C8E20BE8Q35566610-041BE0CF-CD2C-4FC9-9321-DEB027A5A056Q35656998-42628A95-0CCC-46AF-B959-C12D2461B88DQ35889245-073598CE-6AA8-44FA-AD79-D39A81992DEFQ36056484-2EFCA9CF-B592-4B60-9332-8175DCB08334Q38013789-6D138E68-491E-429F-A074-C97A6F1D0850Q38127011-D3D05C33-4275-4DD9-B635-DFB7593C0D66Q38154958-3C16475E-9669-4EA2-973E-B6A6CDD1223FQ38503330-6FEAE73B-6139-4AAB-A741-A7C78F820BE8Q40087434-747DD465-8020-4595-93F2-E50E74B5E9F3Q40730015-77816270-1CE9-4A27-AE0E-386F69CFE9B2Q41035406-A4B929DE-9BA4-4203-B548-8E4D2FC42EDBQ41769755-EC977485-BB78-4D2B-A5DD-53F88BB30BD3Q45062704-01D0E9A2-8FD3-4ED3-9E03-5BC238B1F2B9Q50119865-A61506DD-4E69-4C30-AF3E-7A902C6C2235Q50358296-ECD30B79-F096-4D6C-BD8E-8FF81B9A6626Q50865329-E020F4E4-DF7C-4842-80B0-C727BCAC6004Q51533953-04140C49-DBEA-43D2-8505-BA04FE89B346Q52695058-76B34740-B5A2-4D0A-8B46-FB5F63DD9C10Q55436442-14424606-294C-4C97-9188-2D0D4521EAF0
P2860
Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Mechanisms underlying allergy ...... lergenic allergen derivatives.
@en
Mechanisms underlying allergy ...... lergenic allergen derivatives.
@nl
type
label
Mechanisms underlying allergy ...... lergenic allergen derivatives.
@en
Mechanisms underlying allergy ...... lergenic allergen derivatives.
@nl
prefLabel
Mechanisms underlying allergy ...... lergenic allergen derivatives.
@en
Mechanisms underlying allergy ...... lergenic allergen derivatives.
@nl
P2860
P1433
P1476
Mechanisms underlying allergy ...... lergenic allergen derivatives.
@en
P2093
Birgit Linhart
P2860
P304
P356
10.1016/J.VACCINE.2011.11.011
P407
P577
2011-11-17T00:00:00Z